Kei Ohnuma
Impact in
- Oncology top 1%
- Peptidase Inhibition and Analysis
-
- Diabetes Treatment and Management
Papers in
- Oncology 70
- Peptidase Inhibition and Analysis 62
-
- Glycosylation and Glycoproteins Research 10
- Signaling Pathways in Disease 10
- Co-authors
- Chikao Morimoto (85 shared papers)Nam H. Dang (63 shared papers)Satoshi Iwata (25 shared papers)Ryo Hatano (34 shared papers)Hirotoshi Tanaka (15 shared papers)Osamu Hosono (24 shared papers)Tadanori Yamochi (12 shared papers)Masahiko Uchiyama (9 shared papers)
- Journals
- Biochemical and Biophysical Research Communications (10 papers)Modern Rheumatology (8 papers)The Journal of Immunology (6 papers)British Journal of Cancer (5 papers)PLoS ONE (4 papers)
- Partner nations
- JapanUnited StatesFrance
In The Last Decade
Kei Ohnuma
102 papers receiving 3.5k citations
Peers
Comparison fields: 5 of 106
- Oncology 1.6k
- Endocrinology, Diabetes and Metabolism 602
- Cellular and Molecular Neuroscience 641
- Immunology 699
- Cancer Research 430
Countries citing papers authored by Kei Ohnuma
This map shows the geographic impact of Kei Ohnuma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kei Ohnuma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kei Ohnuma more than expected).
Fields of papers citing papers by Kei Ohnuma
This network shows the impact of papers produced by Kei Ohnuma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kei Ohnuma. The network helps show where Kei Ohnuma may publish in the future.
Co-authors
The 25 scholars most cited alongside Kei Ohnuma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 105 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 220 | |
| 2 | 2017 | 214 | |
| 3 | 2008 | 207 | |
| 4 | 2001 | 151 | |
| 5 | 2005 | 135 | |
| 6 | 2003 | 122 | |
| 7 | 2007 | 115 | |
| 8 | 2004 | 105 | |
| 9 | 2007 | 105 | |
| 10 | 2007 | 81 | |
| 11 | 2000 | 77 | |
| 12 | 2013 | 76 | |
| 13 | 2012 | 74 | |
| 14 | 2005 | 72 | |
| 15 | In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299. | 2001 | 64 |
| 16 | 2005 | 63 | |
| 17 | 2002 | 63 | |
| 18 | 2006 | 59 | |
| 19 | 2011 | 58 | |
| 20 | 2018 | 56 |
About Kei Ohnuma
Kei Ohnuma is a scholar working on Oncology, Molecular Biology, Immunology, Cellular and Molecular Neuroscience and Cancer Research, having authored 105 papers that have together received 3.6k indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (62 papers), Neuropeptides and Animal Physiology (17 papers), Protease and Inhibitor Mechanisms (12 papers), Immune Cell Function and Interaction (12 papers), Glycosylation and Glycoproteins Research (10 papers), Hematopoietic Stem Cell Transplantation (10 papers), Signaling Pathways in Disease (10 papers) and Neuroendocrine Tumor Research Advances (8 papers). The work is most often cited by research in Oncology (1.6k citations), Endocrinology, Diabetes and Metabolism (602 citations), Cellular and Molecular Neuroscience (641 citations), Immunology (699 citations) and Cancer Research (430 citations). Kei Ohnuma has collaborated with scholars based in Japan, United States and France. Frequent co-authors include Chikao Morimoto, Nam H. Dang, Satoshi Iwata, Ryo Hatano, Hirotoshi Tanaka, Osamu Hosono, Tadanori Yamochi, Masahiko Uchiyama, Taketo Yamada and Seiji Kobayashi. Their work appears in journals such as Biochemical and Biophysical Research Communications, Modern Rheumatology, The Journal of Immunology, British Journal of Cancer and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.